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Abstract
Background: Chikungunya is an Aedes -borne disease characterised by febrile
arthralgia and responsible for massive outbreaks. We present a prospective clinical
cohort study and a retrospective serological study relating to a CHIK outbreak, in
the Republic of Congo in 2011.
Methodology and Findings: We analysed 317 suspected cases, of which 308
(97.2%) lived in the city of Brazzaville (66.6% in the South area). Amongst them, 37
(11.7%) were CHIKV+ve patients (i.e., biologically confirmed by a real-time RT-PCR
assay), of whom 36 (97.3%) had fever, 22 (66.7%) myalgia and 32 (86.5%)
arthralgia. All tested negative for dengue. The distribution of incident cases within
Brazzaville districts was compared with CHIKV seroprevalence before the outbreak
(34.4% in 517 blood donors), providing evidence for previous circulation of CHIKV.
We applied a CHIK clinical score to 126 patients recruited within the two first day of
illness (including 28 CHIKV+ves (22.2%)) with sensitivity (78.6%) and specificity
(72.4%) values comparing with those of the referent study in Reunion Island. The
negative predictive value was high (92%), but the positive predictive value (45%)
indicate poor potential contribution to medical practice to identify CHIKV+ve
patients in low prevalence outbreaks. However, the score allowed a slightly more
accurate follow-up of the evolution of the outbreak than the criterion
"fever+arthralgia". The complete sequencing of a Congolase isolate
(Brazza_MRS1) demonstrated belonging to the East/Central/South African lineage
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and was further used for producing a robust genome-scale CHIKV phylogenetic
analysis.
Conclusions/Significance: We describe the first Chikungunya outbreak declared
in the Republic of Congo. The seroprevalence study conducted amongst blood
donors before outbreak provided evidence for previous CHIKV circulation. We
suggest that a more systematic survey of the entomological situation and of
arbovirus circulation is necessary in Central Africa for better understanding the
environmental, microbiological and sociological determinants of emergence.
Introduction
Chikungunya virus (CHIKV, family Togaviridae, genus Alphavirus), is a classical
arbovirus [1], discovered more than 50 years ago in East Africa [2]. It is
responsible for acute febrile arthralgia -the name "Chikungunya" refers to the
stooped posture characterising the infected patients [3]- with possible
complications at the acute phase (e.g. neurological forms) but also possible long-
term persistence of rheumatic symptoms [4, 5]. Over the last decade, CHIKV has
been responsible for significant outbreaks involving millions of human cases in
Eastern and Central Africa, the Indian Ocean, India and South-East Asia, and a
limited - but alarming - number of autochthonous cases in Europe and, more
recently, the Americas [6]. CHIKV is usually transmitted to humans by Aedes
(Stegomyia) aegypti mosquitoes [7]. However, since 2005, it has been shown that
an increasing number of transmission cases implicated Aedes (Stegomyia)
albopictus mosquitoes. In a previous study [8], we provided three distinct
examples (in the Indian Ocean islands, India and Central Africa) of the
independent acquisition of a single adaptive mutation in CHIKV that, when
exposed to Aedes albopictus, acquired a mutation in the envelope gene (E1,
A226V) that has been reported to provide a selective advantage for the virus to be
transmitted by this mosquito [9, 10].
CHIKVs are currently subdivided into three genotypes (Asian, East/Central/
South African (ECSA), and West African) and the genome consists of a single
positive strand of RNA that encodes four non-structural proteins involved in virus
replication and pathogenesis, and five structural proteins that compose the
virions.
Since its first isolation in 1952 in East-Africa [3], CHIKV has caused multiple
outbreaks in the Old World. In both Africa and Asia, they were reported to be
unpredictable, with a variable interval between each epidemic. In 2004, an
outbreak occurred in Kenya, which spread over the Indian Ocean region with an
unprecedented magnitude [11, 12]. Epidemics were subsequently reported in
Senegal, Sudan, Cameroon, Gabon and for the first time in the Republic of Congo
in 2011 [13].
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The first ProMed-mail alert concerning a probable chikungunya outbreak
affecting the Republic of Congo was published on June 13th 2011 [14]. The first
suspected cases appeared in early June in the district of Bacongo and Make´le´ke´le´
in the south of Brazzaville. CHIKV infections were quickly confirmed by a
laboratory in neighbouring Gabon [15]. According to the World Health
Organisation (WHO), as of July 26th, a total of 11,083 suspected cases had been
reported, of which 91% (10,066/11,083) originated from the Department of
Brazzaville and 9% (1,117/11,083) from the Department of Pool (located in the
south of the Republic of Congo). The most affected area in Brazzaville was the
district of Make´le´ke´le´, which accounted for 65.7% of the total number of reported
cases (7,279 cases) [16, 17].
Since 2006, a large amount of information regarding the clinical manifestations
of CHIKV has been collected which relates to both "standard" and complicated
presentations. Nevertheless, with a few exceptions (i.e., the original CHIKV
description, the Cameroon outbreak in 2006 and the Gabon outbreak in 2010),
most clinical studies were conducted outside Africa [3, 18, 19].
Here, we present findings relating to the CHIK outbreak in the Republic of
Congo in 2011. The study included three complementary objectives: (i) a clinical
study in which we assessed a recently published clinical score, originally
established in a different setting [20]; (ii) an epidemiological study based on the
analysis of incident laboratory confirmed cases and a seroprevalence analysis
conducted amongst blood donors in the pre-epidemic period; (iii) a molecular
study, in which we produced complete sequences and a robust genome-scale
phylogenetic analysis of the Congolese virus together with a recent dataset of
complete sequences.
Materials And Methods
Design
We present a CHIKV retrospective, cross-sectional, serological study followed by a
prospective clinical cohort study performed during the CHIK outbreak in the
Republic of Congo in 2011.
Setting
This study took place in Brazzaville, the political and administrative capital city of
the Republic of Congo. Brazzaville is located in the south of the country, on the
north shore of the Congo River across from Kinshasa (Democratic Republic of
Congo). Brazzaville was, at the onset of the study, divided into seven districts
(namely: Make´le´ke´le´, Bacongo, Poto-Poto, Moungali, Ouenze, Talangai and
Mfilou). To facilitate our analysis, we grouped the districts into three areas
according to the geographical location (Make´le´ke´le´, Bacongo - South), (Poto-
Poto, Moungali, Ouenze, Mfilou - Center) and (Talangai - North).
According to the "Centre National de la Statistique et des Etudes Economiques"
(CNSEE), on 1st January 2011, 3,697,490 people lived in the Republic of Congo of
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which 1,373,382 lived in Brazzaville. The characteristics and spatial distribution of
the general population of Brazzaville in the different districts is presented in the
table 1.
In Brazzaville, healthcare facilities consist of six public hospitals and numerous
integrated care centres.
Table 1. Characteristics of the populations studied in Brazzaville with reference to the general population.
Serological study (N5517) Clinical study (N5308) General population (N51 373 382)
Age
Mean 33.85 29.17 21.00
Median 32 29.00 23.44
Extremes 18–60 1–68 0–90+
SD 10.58 15.20 16.99
Age group; n (%)
#17 - 69 (22.4) 578 156 (42.2)
18–29 221 (42.7) 86 (27.9) 351 764 (25.6)
30–39 140 (27.1) 72 (23.4) 209 414 (15.2)
40–49 101 (19.5) 47 (15.3) 120 971 (8.8)
50–59 55 (10.6) 34 (11.0) 63 119 (4.6)
60–69 - - 30 805 (2.2)
$70 - - 19 153 (1.4)
Gender
M/F 391/126 133/173 677 599/695 783
Gender ratio 3.1 0.76 0.97
Occupation
Work/Employed 293 (56.7) 77 (25.0)
Student 100 (19.3) 118 (38.3)
Unemployed 124 (24.0) 87 (28.2)
Children (,13yo) not attending school - 26 (8.4)
Districts of Brazzaville; n (%)
Makelekele 90 (17.4) 175 (56.8) 298 292 (21.7)
Bacongo 124 (24.0) 30 (9.7) 98 782 (7.2)
Poto-Poto 30 (5.8) 6 (1.9) 93 106 (6.8)
Moungali 35 (6.8) 10 (3.2) 166 719 (12.1)
Ouenze 54 (10.4) 9 (2.9) 182 057 (13.3)
Talangai 130 (25.1) 58 (18.8) 337 986 (24.6)
Mfilou 54 (10.4) 20 (6.5) 196 440 (14.3)
Brazzaville by zone; n (%)
South 214 (41.4) 205 (66.6) 397 074 (28.9)
Centre 173 (33.5) 45 (14.6) 638 322 (46.5)
North 130 (25.1) 58 (18.8) 337 986 (24.6)
doi:10.1371/journal.pone.0115938.t001
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Population and procedures
Seroprevalence study
before the 2011 CHIKV outbreak, sera from blood donors collected in Brazzaville
before June 2011 (from March 29th to May 26th) were provided by the national
Congolese blood bank (Centre National de Transfusion Sanguine, CNTS).
Clinical study
The CNTS and the national laboratory of public health (Laboratoire National de
Sante´ Publique, LNSP) of the Republic of Congo designed and conducted this
clinical study in collaboration with the French institute for research and
development (IRD).
The study started on June 2nd 2011 [week (W) 22:W22] and finished on July
28th 2011 (W30). During this period, all patients suspected of CHIK who
consulted any of the health care facilities in Brazzaville were eligible for enrolment.
A suspected case was defined as a patient with at least one of the following
symptoms: fever, arthralgia, myalgia, headache or rash. All suspected cases that
reported such symptom(s) in the previous eight days and agreed to participate to
the study were included. Were excluded patients who did not report any symptom
of the case definition and those who had symptom(s) but did not will to
participate.
After inclusion, medical examination and interview were completed, data were
collected on a standardised questionnaire [20], which included age, gender,
residence, time of onset, concomitant treatments, intensity of symptoms and
location of arthralgia. The quality of sleep was assessed by self-reported visual
analogic scale (VAS) from ‘‘very bad’’ (VAS50) to ‘‘very good’’ (VAS5100).
Venous blood samples were drawn using two 5 mL EDTA and one 4 mL plain
tubes which were immediately centrifuged. Serum/plasma aliquots were kept at
280 C˚.
Virological investigations were retrospectively performed in the UMR_D 190
laboratory, in Marseille, France.
The case definition of CHIKV positive patients (CHIKV+ves) relied on
retrospective laboratory confirmation of CHIKV infection (positive CHIKV
specific RT-PCR).
The patients who were included within the two first days of illness were used to
compare the clinical presentation of CHIKV+ve and CHIKV negative (CHIKV-
ve) patients.
Ethical considerations
Oral (patients in Emergency units who accepted to fill the study questionnaire)
and/or written (blood donors) consent was obtained for each person enrolled in
the study. The project and the consent procedure were approved by the Congolese
Research in Health Sciences Ethics Committee as an extension of an ongoing
Chikungunya Fever Outbreak in the Republic of Congo, 2011
PLOS ONE | DOI:10.1371/journal.pone.0115938 December 26, 2014 5 / 21
To estimate the seroprevalence of CHIKV infection in the population of Brazzaville
study of the arbovirus epidemiology in Republic of Congo (N˚ 00000065 DGRST/
CERSSA).
Negative control serum samples for serological analyses (PRIAM study) were
collected after obtaining written informed consent from all participants.
Laboratory analysis
Molecular diagnosis
Nucleic acids were extracted from serum samples using the EZ1 Virus Mini Kit v2
and an EZ1 advanced XL Biorobot workstation (Qiagen). Detection of viral
genomes was performed using a one-step TaqMan real time RT-PCR procedure
and the kit SuperScript III Platinum One-Step Quantitative RT-PCR System with
ROX (Life Technologies) for the CHIKV and the dengue virus (DENV), as
previously described [21, 22, 23]. In addition, plasma samples were tested for the
presence of Plasmodium falciparum genomes using a previously reported real time
PCR procedure targeting the P. falciparum aquaglyceroporin gene [21, 22, 23] and
the Platinum Quantitative PCR SuperMix-UDG (Life Technologies).
Serological analysis
Specific IgG against CHIKV were detected using an enzyme-linked immunosor-
bent assay (ELISA) method and a standard operating procedure [24]. The
National Reference Centre for arboviruses provided a panel of 328 serum samples
from blood donors living in metropolitan France, which tested negative for IgG to
CHIKV (PRIAM study). This panel was used to determine the cut-off of the test
(established as the mean of the adjusted OD values of these negative controls plus
two standard deviations).
Virus isolation
Propagation onto cell cultures was carried out in a biosafety level 3 laboratory.
Virus isolation was attempted using serum samples with a positive RT-PCR result
by inoculating 100 mL of serum directly onto C6/36 Aedes albopictus cells. Viral
growth was identified by combining the observation of gross cytopathic effect and
a specific molecular detection using the same real time specific RT-PCR as
described above.
CHIKV genome sequencing
A complete genome sequence (excluding the first 18 nucleotides of the 5’UTR and
the 20 nucleotides upstream the polyA tail) was produced from the first passage of
a CHIKV strain isolated from a 3-year old boy presenting with fever and
dermatological signs and who was living in the district of Make´le´ke´le´, Brazzaville.
Nucleic acids were extracted from cell culture supernatants using the EZ1 Virus
Mini Kit v2 and the EZ1 Biorobot (Qiagen). Primers previously designed to
sequence the LR2006 OPY1 CHIKV strain were used to generate PCR products
with the Access RT-PCR System (Promega). Amplicons were purified and
sequenced using the Sanger method and the BigDye Terminator v3.1 Cycle
Sequencing Kit on an ABI Prism 31310X Genetic Analyser sequencer (both from
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Life technologies). Analysis of sequencing chromatograms was performed using
the Sequencher 4.9 software (Gene Codes Corporation).
Statistical analysis
To describe the clinical characteristics of the population studied, we performed a
bivariate analysis and p-values were determined for qualitative variables with a
Fisher’s exact test; for continuous variables a Mann Whitney nonparametric test
was used. Correlations were assessed using the Spearman nonparametric test (rho
coefficient, r). The patients included within the 2 first days of illness were used to
compare CHIKV+ve patients to CHIKV-ve patients.
With regard to a previous study [20], we evaluated a clinical score for the
diagnosis of CHIK amongst patients included within the two first day of illness.
This score was previously presented from a cohort of suspected CHIK outpatients
during the Reunion outbreak in 2006. Our score was based exclusively on clinical
data and particularly on the presence or absence of 3 symptoms: arthralgia in at
least one hand, arthralgia in at least one wrist and minor or absent myalgia [20].
In the Reunion Island referent population, the clinical score had a Sensitivity of
76%, a Specificity of 73%, a PPV and NPV of 87% and 55% respectively. The
probability (p) of having been infected by CHIK was estimated, using logistic
regression, as follows:
p51/(1+exp(1.609)6exp(21.4506MCP+)6exp(21.7326W+)6exp(22.0446MYOPAIN))
where each covariate was validated if equal to 1, otherwise 0.
Sensitivity (Se), specificity (Sp), predictive values –positive (PPV) and negative
(NPV) – were calculated and yielded a Receiver Operating Characteristic (ROC)
curve and the area under the curve (AUC).
All statistical analyses were performed with the IBM SPSS statistic 21 software.
The alpha level of significance chosen was 0.05.
Phylogenetic analysis
The two open reading frame (ORFs) of available complete CHIKV genomes were
manually extracted, concatenated using Mega 5.1 [25] and aligned with ClustalW
[26] according to the amino acid sequence. This included sequences available
from the GenBank database, together with the sequence of Congolese isolate, also
a number of previously unreleased sequences from the Indian Ocean Region and
Italy. Two codon positions were removed from the alignment: (i) residue 1,857 of
the non-structural polyprotein (associated with read through within the NSP4
protein) which is non-informative for phylogenetic reconstructions and (ii)
residue 1,035 of the structural polyprotein (associated with the single mutation
providing an assumed selective advantage for transmission by Aedes albopictus at
E1 position 226) since variability at this site may be driven by convergent adaptive
evolution [8].
The phylogenetic tree was inferred using the maximum likelihood method with
the RAxML 7.3.0 program [27]. Mega 5.1 was used to select the best-fit model for
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the analysis (GTR model of nucleotide substitution with gamma-plus-invariant-
sites-distributed rates of change among sites) [25] and a bootstrap analysis was
performed (1,000 replicates). The tree was edited with FigTree v1.3.1.
Results
Serological and Clinical studies
Population studied
Overall, 517 serum samples of blood donors were collected and analysed before
the outbreak, between March 29th, 2011 and May 26th, 2011. The gender ratio
(M/F) was 3.1 and median age of 32 (Table 1).
From June 2nd 2011 (W22) to July 28th 2011 (W30), 317 suspected cases of
CHIKV were recorded, of which 308 (97.2%) lived in the city of Brazzaville and,
for the majority of cases, in the district of Make´le´ke´le´ (175/308, 56.8%) (Table 1).
Nine patients originated from other departments: eight (2.5%) from the Pool
department and one (0.3%) from the north of country. The population studied
was young (median age: 30) and mostly urban. The gender ratio (M/F) was 0.77
and 135 (42.6%) patients were enrolled within 2 days from the onset of the
disease.
Three distinct periods corresponding the number of inclusions of suspected
cases were defined: 45 (14.2%) patients during W22–26, 132 (41.6%) during
W27–28 and 140 (44.2%) during W29–30.
The inclusion curve of suspected cases of our study was compared with the
WHO epidemic curve (Fig. 1). 135 patients were included within the two first
days of illness, 100 between days 3 and 4, and 82 between days 5 and 7.
Geographical distribution of cases
The distribution of cases within the seven districts of Brazzaville was studied and
compared with the prevalence of antibodies to CHIKV in blood donors before the
outbreak.
Among the 517 blood donors collected, 178 (34.4%) showed positive IgG
against CHIKV. The seropositivity rate was 16.3% (29) in Make´le´ke´le´, 28.7% (51)
in Bacongo, 6.2% (11) in Poto-Poto, 2.8% (5) in Moungali, 7.3% (13) in Ouenze,
9.6% (17) in Mfilou, and 29.2% (52) in Talangai. Districts were grouped into
three areas. The seropositivity rate was, in decreasing order: 40% (52/130) in the
North Area (Talangai district); 37.4% (80/214) in the South Area (Make´le´ke´le´ and
Bacongo districts); 26.6% (46/173) in the Central Area (Poto-Poto, Ouenze and
Mfilou districts) (Fig. 2A). The distribution of suspected and incident cases of
CHIKV is presented in Fig. 2B and reveals that a vast majority of cases occurred in
the South district. For each area, the CHIKV seroprevalence before the outbreak,
the percentage of suspected cases that were confirmed and the contribution to the
total number of positive cases are presented in Fig. 2.
Chikungunya Fever Outbreak in the Republic of Congo, 2011
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Molecular diagnosis
Amongst the 317 patients studied, 37 (11.7%) had a positive PCR result for
CHIKV (CHIKV+ve patients). Of the 135 patients who enrolled early (two first
days), 32 were CHIKV+ve (23.7%). All serum samples were negative for DENV
genome detection and five CHIKV-ve samples had positive qPCR detection for P.
falciparum.
The evolution of the positivity rate (i.e., during W22–26, W27–28 and W29–30)
is shown in Fig. 3. It drops from,55% during the first 5 weeks of the outbreak to
less than 15% during the last two weeks studied.
Clinical description of CHIKV+ve patients
Amongst the 37 CHIKV+ve patients, the median age was 33 years old; the gender
ratio (M/F) was 0.95. Detection of CHIK occurred in patients consulting on
average 1.8 days (range, 0 to 5 days) after the onset of symptoms; 32 (86.5%)
consulted from day 0 to day 2, four (10.8%) on day 3, and one (2.7%) on day 5.
At the time of the consultation, 36 (97.3%) patients had fever, 22 patients
(66.7%) declared myalgia and 32 (86.5%) arthralgia, including 18 (48.6%) with an
intensity assessed as important. Amongst the 32 patients with musculoskeletal
pain, joint pain was mostly polyarticular: on average, 5 joints per patient were
affected (SD 3) and 18 (56.2%) had more than three joints that were affected.
Arthralgia occurred preferentially in the small upper joints (wrists and hands)
followed by knees, ankles and feet.
Five (13.5%) patients declared no arthralgia but had fever and dermatologic or
digestive disorders.
Skin lesions were noticed in 16 (43.2%) patients, 14 (37.8%) of which also had
pruritus. Digestive symptoms, consisting of diarrhoea, nausea and vomiting were
described in a limited number (7) of cases (18.9%).
General symptoms were also recorded: headache in 23 (63.9%) cases, asthenia
in 35 (94.6%), and chills in 12 (32.4%). The quality of sleep was severely impacted
with 27 (73%) patients reporting "very bad".
Fig. 1. Weekly distribution of CHIK suspected cases in Republic of Congo, 2011. Note: The reuse figures
of WHO curve were initially published under an open-access license (CC-BY)
doi:10.1371/journal.pone.0115938.g001
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Fig. 2. In three areas of Brazzaville city: distribution of CHIKV seropositive (IgG) blood donors before the outbreak (A); distribution of suspected
and confirmed (CHIKV+ve patients) cases during the outbreak (B); summary of seroprevalence and incidence data (C); distribution of CHIKV+ve
cases (D). Of note, suspected cases included patient who reported evocative symptoms in the previous eight days. Since the duration of viraemia is usually
shorter, this may lead to underestimate the ratio CHIKV+ve/CHIK suspected cases, but does not hamper the comparison of values amongst the three areas
considered.
doi:10.1371/journal.pone.0115938.g002
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In bivariate analysis, an increase of age was correlated with a higher intensity of
headache (p,0.001, r50.687), myalgia (p,0.01, r50.523), poor quality of sleep
(p,0.05, r50.345), and a lower frequency of diarrhoea (p,0.001, r520.575).
Gender was not associated with specific symptoms or severity of symptoms.
Clinical description of patients with positive P. falciparum detection
Amongst the five patients with positive sample for P. falciparum, two (40%)
complained about cervical or lumbar arthralgia. None reported arthralgic pain for
small joints (i.e., wrists or hands.).
Comparison between CHIKV+ve and CHIKV-ve patients at the early stage of
disease
A vast majority of CHIKV+ve patients (86.5%) consulted before day 3.
Accordingly, a comparison between CHIKV+ve and CHIKV-ve patients was
performed for those who consulted within 2 days from the onset of symptoms
(i.e., 32 CHIKV+ve and 103 CHIKV-ve patients). The main findings are
summarised in Table 2.
No significant difference in age or gender ratio was identified. CHIKV+ve
patients complained more frequently about arthralgia, notably for small joints
such as wrists, hands, ankles, feet than CHIK-ve patients. The number and
intensity of joint pains were also higher in CHIKV+ve patients. CHIKV+ve
patients notified more frequently pruritus or "burn under the feet" and an
impaired quality of sleep compared to CHIKV-ve patients. No significant
difference between patients who had myalgia was noticed. By contrast, CHIKV+ve
patient less frequently reported shiver and no significant difference was observed
for dermatological and gastro-intestinal symptoms.
Fig. 3. Weekly trend of CHIKV+ve patients (confirmed cases), "CHIK probable" and "CHIK possible"
cases (according to clinical diagnostic score) and "arthralgia + fever" cases, Republic of Congo, 2011.
Curves for ‘‘CHIKV+ve patients’’ and "arthralgia + fever" were created with the 135 patients enrolled within the
2 first days of the illness. Nine patients were excluded for the calculation of the clinical score (incomplete
information regarding myalgia or arthralgia).
doi:10.1371/journal.pone.0115938.g003
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Table 2. Demographic and clinical characteristics of CHIKV+ve and CHIKV-ve patients included at Day 1-Day 2.
CHIKV+ve (n532)
CHIKV-ve
(n5103) p-value Odd Ratio (CI 95%)
Age; mean (SD) 28.88 (18.13) 27.04 (16.91)
Sex; n (%) M 15 (46.9) 35 (34.0) 0.212 0.58 (0.26;1.31)
F 17 (53.1) 68 (66.0)
Fever; n (%) 31 (96.9) 100 (97.1) 1.0 0.93 (0.093;9.26)
Arthralgia; n (%) 27 (84.4) 56 (54.4) 0.0031 4.53 (1.62;12.69)
Number mean (SD) 3.81 (2.96) 1.83 (2.32)
Intensity; n (%) 0.000001 ND
Absent 5 (15.6) 47 (45.6)
Minor 1 (3.1) 11 (10.7)
Moderate 10 (31.3) 38 (36.9)
Important 16 (50.0) 7 (6.8)
Localisation; n (%) Wrist 25 (78.1) 36 (35.0) 0.00003 6.65 (2.62;16.86)
Hands (MCP+PIP) 24 (75.0) 29 (28.2) 0.000003 7.66 (3.09;18.98)
Ankles 14 (43.8) 22 (21.4) 0.021 2.86 (1.23;6.65)
Feet 12 (37.5) 10 (9.7) 0.00059 5.58 (2.12;14.7)
Knees 12 (37.5) 25 (24.3) 0.174 1.87 (0.80;4.36)
Cervicalgia 10 (31.3) 22 (21.4) 0.341 1.67 (0.69;4.05)
Lombalgia 10 (31.3) 20 (19.4) 0.222 1.88 (0.77;4.61)
Shoulders 8 (25.0) 12 (11.7) 0.086 2.53 (0.93;6.88)
Elbows 7 (21.9) 12 (11.7) 0.155 2.12 (0.76;5.96)
Headache; n (%) 21 (67.7) 58 (56.9) 0.305 1.59 (0.68;3.72)
Asthenia; n (%) 32 (100.0) 93 (90.3) 0.117 ND
Myalgia; n (%) 18 (64.3) 56 (57.1) 0.524 1.35 (0.56;3.22)
Moderate or Important 15 (53.6) 36 (36.7) 0.129 1.99 (0.85;4.64)
Shiver; n (%) 11 (34.4) 58 (56.3) 0.042 0.41 (0.18;0.93)
Dermatological signs; n
(%)
14 (43.8) 33 (32.0) 0.288 1.65 (0.73;3.72)
Nausea or Vomiting; n
(%)
7 (21.9) 23 (22.3) 1.00 0.97 (0.37;2.54)
Diarrhoea; n (%) 7 (21.9) 19 (18.4) 0.798 1.24 (0.47;3.28)
Respiratory signs; n (%) 1 (3.1) 4 (3.9) 1.00 0.80 (0.09;7.41)
Haemorrhagic signs; n
(%)
0 (0.0) 1 (1.0) 1.00
Pruritus; n (%) 11 (34.4) 16 (15.5) 0.025 2.85 (1.15;7.03)
Burn under the feet; n
(%)
4 (12.5) 2 (1.9) 0.028 7.21 (1.26;41.44)
Quality of Life; n (%)
Capacity to perform nor-
mal activity
0.129 ND
Very Bad 9 (28.1) 16 (15.5)
Medium 23 (71.9) 86 (83.5)
Very good 0 (0.0) 1 (1.0)
Health Status 0.676 ND
Very Bad 2 (6.3) 5 (4.9)
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Diagnostic score
A total of 135 patients was enrolled within 2 days from the onset of the disease.
Nine patients were excluded (incomplete informations regarding myalgia or
arthralgia) and the clinical score was therefore applied to 126 patients: 23 (18.3%)
were "probable" cases, 26 (20.6%) "possible" cases, and 77 (61.1%) "not probable"
cases. Prevalence was (28/126) 22.2% in this population. The performance of the
score for detecting "possible + probable" cases was as follows: sensitivity, 78.6%;
specificity, 72.4%; PPV, 45%; NPV, 92.2%. The ROC curve had an AUC50.76
(p,0.001). In comparison, amongst the 135 patients enrolled within the 2 first
days of the illness, the sensitivity, specificity, PPV and NPV of the criterion
"arthralgia and fever" in this population were as follows: 85.7%, 44.9%, 30.8%,
91.7% respectively.
The percentages of "possible" and "probable" cases, in patients reporting
"arthralgia and fever", and of CHIKV+ve patients (laboratory confirmed) was
followed (W22–26, W27–28, W29–30) and are presented in Fig. 3. The
distribution of "probable" and "possible + probable" cases faithfully follows that of
confirmed cases (with a slight underestimation and overestimation of the
incidence rate, respectively), providing a more acute estimate of the actual
epidemiological evolution than the simple "fever + arthralgia" criterion.
Phylogenetic analysis
Phylogenetic analysis of the complete sequence of isolate Brazza_MRS1 (Genbank
accession number pending: KP003813) revealed that it belongs to the East/
Central/South African (ECSA) lineage (Fig. 4). As previously reported, this
lineage splits into three distinct clades [28]: the first (ECSA1) contains Ross and
S27-African prototype strains and a variety of strains from West, Central, East and
South Africa; the second (ECSA2) contains a majority of strains originating from
Central Africa (e.g., HB78 and UgAG4155 strains); the third contains strains
which recently emerged in the Indian Ocean basin and in Asia (called Indian
Ocean Outbreak Group in Fig. 4). Strain Brazza_MRS1 falls into the ECSA2
Table 2. Cont.
CHIKV+ve (n532)
CHIKV-ve
(n5103) p-value Odd Ratio (CI 95%)
Medium 30 (93.8) 97 (94.2)
Very good 0 (0.0) 1 (1.0)
Quality of Sleep 0.009 ND
Very Bad 25 (78.1) 53 (51.5)
Medium 7 (21.9) 49 (47.6)
Very good 0 (0.0) 1 (1.0)
Use of Paracetamol; n
(%)
32 (100.0) 102 (99.0) 1.00 ND
Use of NSAIDs; n (%) 11 (34.4) 19 (18.4) 0.086 2.32 (0.96;5.60)
doi:10.1371/journal.pone.0115938.t002
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group and is closely related to GABOPY1 (KP003812), a strain isolated in 2007
during an outbreak in Gabon. This grouping is supported by 100% bootstrap
values for the clade itself and for the sister relationship between Brazza_MRS1 and
GABOPY1. The concatenated sequences of the two ORFs of these two strains are
99.6% (11,120/11,166 nt) and 99.5% (3,703/3,722 aa) identical at the nucleotide
and amino acid levels, respectively. The E1-A226V mutation, associated with
adaptation to the mosquito Aedes albopictus, is present in both strains [9, 10].
The complete subtree with all CHIKV genotype ECSA sequences is available in
Fig. 5. Regarding strains associated of the Indian Ocean Outbreak Group, the tree
Fig. 4. Maximum likelihood phylogenetic reconstruction using CHIKV nucleotide complete coding sequences.
doi:10.1371/journal.pone.0115938.g004
Chikungunya Fever Outbreak in the Republic of Congo, 2011
PLOS ONE | DOI:10.1371/journal.pone.0115938 December 26, 2014 14 / 21
topology is similar to that proposed by Volk and collaborators (2010) and
supports the earlier hypothesis [8] that the Indian Ocean and Indian subcontinent
outbreaks emerged independently, presumably from Kenyan or early Comoran
Aedes aegypti-associated CHIKV variants.
We established additional full coding sequences of isolates from Mayotte
(OPY4, 2006, KP003809) and Madagascar (MADOPY1, 2006, KP003808) and
included them in genome-scale analysis. Like all other isolates characterised to
date [9], the Mayotte strain includes the A226V mutation, in contrast with two
2005 available sequences from other Comoran islands. Since both Aedes albopictus
and Aedes aegypti mosquitoes are present in Mayotte, this may imply either that
original A226 strains from Comoros became rapidly adapted to Aedes albopictus,
Fig. 5. Detailed phylogeny of CHIKV genotype ECSA. Subtrees include all nucleotide sequences of CHIKV genotype ECSA extracted from the maximum
likelihood tree presented in the manuscript (Fig. 4). Panel A includes a cladogram with boostrap values (only topology is displayed); a phylogenetic tree in
which horizontal lines are proportional to genetic distances is presented in panel B. Sequence information for each virus corresponds to virus strain name/
date of isolation (when available)/country of isolation/symbol for the amino-acid at the position E1-226. The sequence from the CHIKV strain isolated and
completely sequenced in the present study was named "BRAZZA_MRS1_Jul_2011_Congo_V". The sequences in red were also sequenced by the
UMR_190_EPV (Marseille, France).
doi:10.1371/journal.pone.0115938.g005
Chikungunya Fever Outbreak in the Republic of Congo, 2011
PLOS ONE | DOI:10.1371/journal.pone.0115938 December 26, 2014 15 / 21
or alternatively, that the Mayotte CHIKV strains originated from Reunion island
or Mauritius where a rapid shift to Aedes albopictus-associated strains was
observed [9].
The MADOPY1 strain was isolated in 2006 from a French patient returning
from Madagascar. Interestingly, this strain includes the A226V mutation. This is
in contrast with eight 2006 Malagasy isolates characterised by Schuffenecker and
collaborators [9]. Since both Aedes albopictus and Aedes aegypti mosquitoes are
present in distinct areas of Madagascar, this finding may indicate that both Aedes
albopictus- and Aedes aegypti-associated strains have co-circulated in Madagascar
as early as 2006. The presence of Aedes albopictus-associated virus strains has been
subsequently confirmed in 2007 in a traveller returning from Madagascar [29].
In addition, we analysed and included isolates made from autochthonous
transmission of CHIKV in Europe. Strain OPY6 (2006) was isolated from a case of
autochthonous nosocomial infection in a nurse in metropolitan France [30]. The
index case was a patient returning from Reunion Island. As expected, OPY6
(KP003807) sequence includes the A226V mutation and is grouped with the other
2006 Indian Ocean CHIKV sequences. Other cases were identified in Italy during
the 2007 outbreak. Strains StVE (KP003810) and StBI (KP003811) (isolated from
human cases of autochthonous CHIKV transmission that occurred in Northern
Italy) form a cluster with the previously characterised ITA07-RA1 strain (ML
bootstrap: 100%) (Fallacara and Bonilauri 2008, unpublished), most likely
indicating a single viral introduction event and subsequent spread in Italy in 2007.
All of them contain the A226V mutation, in accordance with the potential local
exclusive transmission by Aedes Albopictus [31].
Discussion
The 2011 chikungunya outbreak investigated in the current study was the first
declared in the Republic of Congo. However, numerous epidemics have been
reported in neighbouring countries during the last 50 years (Angola in 1962, 1970,
1971; Central African Republic in 1978, 1984; Democratic Republic of Congo in
1960, 1999–2000; Cameroon in 2006 and Gabon in 2007–2012) [5]. There is
therefore strong evidence for sustained CHIKV circulation in this African region.
This is confirmed by the seroprevalence study that we conducted in blood donors
three months before the onset of the outbreak and which revealed a 34.4% global
prevalence of antibodies to CHIKV in Brazzaville city.
Little information is available regarding the decisive factors, environmental
characteristics and epidemiological dynamics of chikungunya circulation in the
Republic of Congo. The molecular analysis of a chikungunya strain isolated
during the 2011 outbreak suggested, based on the presence of the A226V adaptive
mutation, that the virus could be transmitted by Aedes albopictus, in agreement
with previous findings in Gabon [32]. An entomological study conducted in the
Make´le´ke´le´ and Mfilou districts during the CHIK outbreak identified CHIKV in
both Aedes albopictus and Aedes aegypti pools [17]. The mosquito infection rate
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was supposedly very high since the authors reported 13 positive pools over 13
tested. We had the opportunity to test a few individual mosquitoes (7 Aedes
aegypti and 4 Aedes albopictus) collected during the course of the epidemic around
health care facilities in Brazzaville by the LNSP, and identified CHIKV in two
Aedes albopictus specimens collected in Make´le´ke´le´ (South Area).
The geographical distribution of CHIKV seroprevalence in March 2011 reveals
the highest values in the North and South areas of Brazzaville city. These estimates
were obtained from a population of blood donors and therefore are associated
with usual limitations associated with this specific population, including an
unbalanced gender ratio and the absence of individuals under the age of 18 years
old. Fig. 2 shows that there is no clear relationship between the CHIKV
seroprevalence status before the outbreak and the geographical distribution of
incident cases in 2011.
The Central Area was still poorly impacted by the outbreak, possibly reflecting
lower exposure to the bite of Aedes mosquitoes in the Central districts. However,
amongst the two areas with high seroprevalence rates, one (North) was associated
with a few incident cases whilst the other (South) hosted the vast majority of
cases. This difference could obviously not be explained by different herd
immunity levels (37.4% vs 40.0%) [33]. Regarding the spatial distribution of
cases, our results are in accordance with WHO findings (72.3% of the total
number of cases (7,279/10,066) were reported in the Make´le´ke´le´ district).
Since the first CHIK descriptions made in Tanzania and Uganda in the 1960’s,
few studies have investigated CHIK outbreaks in Africa [3, 18, 19]. Several recent
studies have suggested that CHIK clinical presentation may differ depending on
the geographic location of the outbreak (e.g., prevalence of persistent arthropathy
or risk factors for severe disease [34, 35]. This may reflect different genetic
backgrounds, co-morbidity factors or prior cross immunity [36, 37].
Here we report the clinical characteristics of laboratory confirmed Congolese
CHIKV patients using a standardised questionnaire that allowed comparison with
previous clinical studies, e.g. in Reunion Island. The incidence of the main clinical
symptoms such as arthralgia, myalgia, dermatological signs and digestive disorder
was within the range of previous reports [18].
Regarding arthralgia, we confirmed that the small joints of the upper member
(wrist and hands) were more frequently affected and had the highest specificity to
differentiate CHIK from other aetiologies. By contrast, the observation that
CHIKV+ve patients had significantly more pruritus and burn under the feet than
CHIKV-ve patients is not part of the canonical description of CHIK.
Differentiating CHIK from other febrile, treatable, aetiologies such as malaria
or bacterial diseases is an important challenge. CHIK also shares some clinical
signs with dengue and can be misdiagnosed in areas where dengue is common.
Recently chikungunya diagnostic scores have been proposed from a cohort of
outpatients during the Reunion Island outbreak [20]. The best results were
obtained when clinical signs were associated with the lymphocyte count. Here, in
the absence of blood cell count, we tested the clinical version of this score in
Congolese suspected cases included within less than two days after the onset of the
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disease. Sensitivity (79% vs 76%) and specificity (72% vs 73%) values were similar
to those obtained in the referent study [20]. These two studies were conducted in
very different environments (e.g., the socio-economic level was much higher, and
the impact of other tropical diseases such as malaria was much lower in Reunion
Island), but had in common the absence of dengue co-circulation. In contrast
with the recent CHIK outbreak that occurred in Gabon [32] and in accordance
with previous reports [17], we did not identify any dengue case amongst the 317
suspected cases investigated. In this epidemiological background, we found that
the clinical score (Se, Sp, PPV, NPV: 78.6%, 72.4%, 45.0%, 92.2% respectively)
permitted a more accurate follow-up of the evolution of the outbreak than the
clinical criterion "fever and arthralgia" (Se, Sp, PPV, NPV: 85.7%, 44.9%, 30.8%,
91.7% respectively). The positive predictive value (45%) associated with possible/
probable cases as defined by the clinical score is however low. This reflects the
lower prevalence observed in the current cohort (22 vs 71% in the referent study)
and indicates that this purely clinical score, even if it performs slightly better than
the criterion "fever + arthralgia", would have been poorly contributory in medical
practice to differentiate CHIKV+ve patients from others during the course of the
Congolese outbreak.
This study provides confirmation that the CHIKV strains that currently
circulate in Central Africa belong to the ECSA2 group. This group includes a
number of strains collected in Central Africa before 1990 (and, anecdotally, the
2000 MH4 Indian strain which is highly similar to a 1982 Uganda strain and may
represent a laboratory contamination, as previously suggested [28]) and
Cameroonese and Gabonese strains identified in 2006–2007. Our phylogentic
analysis includes full-length sequences of a 2007 Gabonese isolate and of a 2011
Congolese strain. They are closely related (Fig. 4) and both of them include
adaptive mutations to Aedes albopictus in the envelope region. Strikingly, analysis
of ECSA strains illustrates the propensity of CHIKV for dispersal and emergence
in remote ecological environments. For example, numerous putative instances of
CHIKV introduction in Singapore or Sri Lanka can be identified (Fig. 5). In
addition, this phylogeny supports the hypothesis that, after 2006, the primary
introduction and spread of CHIKV from Kenya in the Indian subcontinent and
South-East Asia was linked to Aedes aegypti-associated strains (harbouring the E1
residue A226) [8]. In different locations, the selective pressure exerted on CHIKV
through the constraint of having to replicate in a new vector (Aedes albopictus),
was associated with independent events of mutation (A226V) constituting new
examples of evolutionary convergence. For example, the tree is suggestive of at
least two introductions of Aedes aegypti-associated strains in Sri Lanka, followed
by the emergence of Aedes albopictus-adapted strains.
This phylogeny is helpful for proposing a credible evolutionary scenario for
ECSA2 Central African isolates. It formally indicates that these viruses do not
originate from ECSA viruses that have been circulating in the Indian Ocean
Islands, the Indian subcontinent and Asia since 2005, which may have been
brought in by viraemic travellers. Rather, they represent local descendants of
viruses that have been circulating in Central Africa for decades and a scenario of
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convergent evolution that led to adaptation to Aedes albopictus can be proposed,
which suggests that the colonisation of new territories by this mosquito is recent
and massive.
This study suggests sustained circulation of CHIKV belonging to a specific
lineage of the East/Central/South/African (ECSA) genotype in Central Africa.
During the 2011 outbreak, the ‘‘arthralgia+fever’’ criterion had a good sensitivity
for detection of CHIK cases, but low specificity and PPV values. A clinical score
based on arthralgia (in hands and wrists) and myalgia was of poor medical
interest.
The epidemiological and environmental determinants of CHIKV outbreaks in
the region remain poorly characterised.
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